纳络酮与呼吸兴奋剂治疗Ⅱ型呼吸衰竭的疗效观察  

Effect of Naloxone and Respiratory Stimulant on Type Ⅱ Respiratory Failure

作　　者：王真 

机构地区：[1]永州市祁阳县人民医院,湖南祁阳426100

出　　处：《中国医药指南》2014年第23期21-22,共2页Guide of China Medicine

摘　　要：目的探讨纳络酮治疗Ⅱ型呼吸衰竭患者的疗效,以期完善临床应用。方法选取2010年3月至2013年8月于我院就诊的80例慢性Ⅱ型呼吸衰竭患者,根据随机化原则分成试验组和对照组,每组各40例,试验组应用盐酸纳络酮治疗,对照组患者应用呼吸兴奋剂治疗,探讨两组治疗前后症状改善情况以及动脉血气改变。结果两组患者经治疗后临床症状均得到显著改善,两组之间相比有明显差异(P<0.05)。经过治疗,试验组与对照组患者PaO2水平升高,PaCO2降低,两组之间具有显著性差异(P<0.01)。结论纳络酮用于治疗慢性Ⅱ型呼吸衰竭可明显改善患者通气。Objective To evaluate the naloxone in the treatment of patients with type II respiratory failure in efficacy, with a view to improving the clinical application. Methods From March 2010 to August 2013 in our hospital treatment of 80 cases of patients with chronic type 12 respiratory failure, based on the principle of randomization into test group and a control group of 40 patients each, a pilot group application of naloxone bydrochloride treatment, respiratory stimulant treatment control group application to examine two sets of symptoms, arterial blood gas changes before and after treatment. Results The two groups of patients with clinical symptoms were significantly improved after treatment, compared with marked differences between the two groups （P〈0.05）. After treatment, test group and control group patients with PaO2 increase in the level of PaCO2 reduction, has a significant difference between the two groups （P〈0.01）. Conclusion Naloxone for the treatment of patients with chronic type II respiratory failure can be greatly improved ventilation.

关 键 词：纳洛酮 呼吸兴奋剂 Ⅱ型呼吸衰竭 

分 类 号：R563.8[医药卫生—呼吸系统]